Immune Therapy for Cancer

被引:500
作者
Dougan, Michael [1 ]
Dranoff, Glenn
机构
[1] Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA
关键词
monoclonal (antibody); inflammation; vaccine; adjuvants; immunotherapy; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; BACILLUS-CALMETTE-GUERIN; TUMOR-NECROSIS-FACTOR; PHASE-III TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; HELICOBACTER-PYLORI INFECTION; METASTATIC BREAST-CANCER;
D O I
10.1146/annurev.immunol.021908.132544
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.
引用
收藏
页码:83 / 117
页数:35
相关论文
共 239 条
[41]   Experience with hepatitis A and B vaccines [J].
Davis, JP .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 :7-15
[42]  
Denton CP, 2007, ARTHRITIS RHEUM-US, V56, P323, DOI 10.1002/art.22289
[43]   Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific kill T cells dentritic cells [J].
Dhodapkar, KM ;
Krasovsky, J ;
Williamson, B ;
Dhodapkar, MV .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (01) :125-133
[44]   Complement activation determines the therapeutic activity of rituximab in vivo [J].
Di Gaetano, N ;
Cittera, E ;
Nota, R ;
Vecchi, A ;
Grieco, V ;
Scanziani, E ;
Botto, M ;
Introna, M ;
Golay, J .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1581-1587
[45]   Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines [J].
Disis, ML ;
Gooley, TA ;
Rinn, K ;
Davis, D ;
Piepkorn, M ;
Cheever, MA ;
Knutson, KL ;
Schiffman, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2624-2632
[46]   The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the US Preventive Services Task Force [J].
Dube, Catherine ;
Rostom, Alaa ;
Lewin, Gabriela ;
Tsertsvadze, Alexander ;
Barrowman, Nicholas ;
Code, Catherine ;
Sampson, Margaret ;
Moher, David .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (05) :365-375
[47]   Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].
Dudley, ME ;
Wunderlich, JR ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Restifo, NP ;
Royal, RE ;
Kammula, U ;
White, DE ;
Mavroukakis, SA ;
Rogers, LJ ;
Gracia, GJ ;
Jones, SA ;
Mangiameli, DP ;
Pelletier, MM ;
Gea-Banacloche, J ;
Robinson, MR ;
Berman, DM ;
Filie, AC ;
Abati, A ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357
[48]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
[49]   Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients [J].
Dudley, ME ;
Wunderlich, JR ;
Shelton, TE ;
Even, J ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :332-342
[50]   A critical function for type I interferons in cancer immunoediting [J].
Dunn, GP ;
Bruce, AT ;
Sheehan, KCF ;
Shankaran, V ;
Uppaluri, R ;
Bui, JD ;
Diamond, MS ;
Koebel, CM ;
Arthur, C ;
White, JM ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2005, 6 (07) :722-729